Ranbaxy Laboratories, a member of the Daiichi Sankyo Group, has launched letrozole tablets 2.5 mg in UK, Romania and France, on Day-1. Letrozole is the bio equivalent of Femara, the innovator product of Novartis, that has a market size of $58 million in UK, $95 million in France and $5.5 million in Romania (Source: Cegedim2010).

Commenting on the Day-1 launch, Debashis Dasgupta, regional director, Ranbaxy, Europe, said, "We are pleased to introduce letrozole at the earliest available opportunity in UK, Romania & France with a view to broadening access to medication. The product will be offered through pharmacies, retail and wholesale stores with immediate effect and will benefit the healthcare system in these EU markets."

Letrozole is an antineoplastics, indicated for the treatment of breast cancer.

Ranbaxy's subsidiary companies, Ranbaxy (UK) Ltd, Terapia Ranbaxy and Ranbaxy Pharmacie Generiques will be marketing this product in UK, Romania and France respectively.